FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

William Trager

Research Profile

Chemicals & Drugs

Anatomy

Microsomes, Liver

Phenomena

Co-author Network

Publications

TOP 3
Michael J Trnka; Catalin E Doneanu; William F Trager
Photoaffinity labeling of P450Cam by an imidazole-tethered benzophenone probe.
Hisashi Suzuki; M Byron Kneller; Dan A Rock; Jeffrey P Jones; William F Trager; Allan E Rettie
Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors.
Sidney D Nelson; William F Trager
The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of William Trager (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Michael J Trnka; Catalin E Doneanu; William F Trager
Photoaffinity labeling of P450Cam by an imidazole-tethered benzophenone probe.
Archives of biochemistry and biophysics 2006;445(1):95-107.
2004: Hisashi Suzuki; M Byron Kneller; Dan A Rock; Jeffrey P Jones; William F Trager; Allan E Rettie
Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors.
Archives of biochemistry and biophysics 2004;429(1):1-15.
2003: Sidney D Nelson; William F Trager
The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(12):1481-98.
2003: John M Neal; Kent L Kunze; René H Levy; Robert A O'Reilly; William F Trager
Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(8):1043-8.
2003: Caiping Yao; Kent L Kunze; William F Trager; Evan D Kharasch; René H Levy
Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(5):565-71.
2002: R C Sachdeo; S K Sachdeo; René H Levy; Anthony J Streeter; FE Bishop; K L Kunze; Gary Mather; Lorin K Roskos; Danny D Shen; K E Thummel; William F Trager; Christopher Curtin; Dennis R Doose; LG Gisclon; Meir Bialer
Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
Epilepsia 2002;43(7):691-6.
2002: Hisashi Suzuki; M Byron Kneller; Robert L Haining; William F Trager; Allan E Rettie
(+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(3):235-9.
2002: Luke Lightning; William F Trager
Characterization of covalent adducts to intact cytochrome P450s by mass spectrometry.
Methods in enzymology 2002;357():296-300.
2001: Caiping Yao; Kent L Kunze; Evan D Kharasch; Y Wang; William F Trager; I Ragueneau; René H Levy
Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.
Clinical pharmacology and therapeutics 2001;70(5):415-24.
2001: Kirk R Henne; Michael B Fisher; K R Iyer; DH Lang; William F Trager; Allan E Rettie
Active site characteristics of CYP4B1 probed with aromatic ligands.
Biochemistry 2001;40(29):8597-605.
2001: M He; Allan E Rettie; J Neal; William F Trager
Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(5):701-11.
2000: S Rao; R Aoyama; M Schrag; William F Trager; Allan E Rettie; Jeffrey P Jones
A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.
Journal of medicinal chemistry 2000;43(15):2789-96.
2000: Luke Lightning; Jeffrey P Jones; Thomas Friedberg; Michael P Pritchard; Magang Shou; Thomas H Rushmore; William F Trager
Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394.
Biochemistry 2000;39(15):4276-87.
1999: D A Erickson; Gary Mather; William F Trager; René H Levy; JJ Keirns
Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(12):1488-95.
1999: M He; Kenneth R Korzekwa; Jeffrey P Jones; Allan E Rettie; William F Trager
Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
Archives of biochemistry and biophysics 1999;372(1):16-28.
1999: Robert L Haining; Jeffrey P Jones; Kirk R Henne; Michael B Fisher; Dennis R Koop; William F Trager; Allan E Rettie
Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
Biochemistry 1999;38(11):3285-92.
1999: Luke Lightning; Raimund Peter; AP Hunter; Robert L Haining; Allan E Rettie; Thomas Friedberg; Michael P Pritchard; Magang Shou; Thomas H Rushmore; William F Trager
Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9.
Biochemistry 1999;38(8):2312-9.
1999: Jean-Marie Nicolas; Philippe Collart; B Gerin; G Mather; William F Trager; R Levy; J Roba
In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(2):250-4.
1998: Luke Lightning; William F Trager
Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins.
Biochemistry 1998;37(38):13184-93.
1998: Luke Lightning; William F Trager
Mechanism-based inactivation of P450 2A6 by furanocoumarins.
Biochemistry 1998;37(28):10047-61.
1998: SC Khojasteh-Bakht; Luke Lightning; Raimund Peter; William F Trager; Sidney D Nelson
(R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6.
Drug metabolism and disposition: the biological fate of chemicals 1998;26(7):701-4.
1998: W Chen; Luke Lightning; SJ Thompson; Raimund Peter; Allan E Rettie; William F Trager; Sidney D Nelson
Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6.
Chemical research in toxicology 1998;11(4):295-301.
1997: Luke Lightning; Raimund Peter; SJ Thompson; Allan E Rettie; William F Trager
Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(12):1407-15.
1997: Joel Morganroth; WH Lyness; JL Perhach; Gary Mather; J E Harr; William F Trager; René H Levy; A Rosenberg
Lack of effect of azelastine and ketoconazole coadministration on electrocardiographic parameters in healthy volunteers.
Journal of clinical pharmacology 1997;37(11):1065-72.
1997: Agnès Tran; Elisabeth Rey; Gérard Pons; M Rousseau; Philippe d'Athis; Georges Olive; Gary Mather; FE Bishop; colleen johnson wurden; RB Labroo; William F Trager; Kent L Kunze; Kenneth E Thummel; J C Vincent; JM Gillardin; F Lepage; René H Levy
Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.
Clinical pharmacology and therapeutics 1997;62(5):490-504.
1997: D J Steward; Robert L Haining; Kirk R Henne; G Davis; Thomas H Rushmore; William F Trager; Allan E Rettie
Genetic association between sensitivity to warfarin and expression of CYP2C9*3.
Pharmacogenetics 1997;7(5):361-7.
1997: K R Iyer; Jeffrey P Jones; J F Darbyshire; William F Trager
Intramolecular isotope effects for benzylic hydroxylation of isomeric xylenes and 4,4'-dimethylbiphenyl by cytochrome P450: relationship between distance of methyl groups and masking of the intrinsic isotope effect.
Biochemistry 1997;36(23):7136-43.
1996: Robert L Haining; A P Hunter; M E Veronese; William F Trager; Allan E Rettie
Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.
Archives of biochemistry and biophysics 1996;333(2):447-58.
1996: J F Darbyshire; K R Iyer; J Grogan; Kenneth R Korzekwa; William F Trager
Substrate probe for the mechanism of aromatic hydroxylation catalyzed by cytochrome P450.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(9):1038-45.
1996: L C Wienkers; colleen johnson wurden; E Storch; Kent L Kunze; Allan E Rettie; William F Trager
Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(5):610-4.
1996: Kent L Kunze; William F Trager
Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(4):429-35.
1996: Douglas J Black; Kent L Kunze; L C Wienkers; B E Gidal; T L Seaton; N D McDonnell; J S Evans; J E Bauwens; William F Trager
Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(4):422-8.
1996: Kent L Kunze; L C Wienkers; Kenneth E Thummel; William F Trager
Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(4):414-21.
1995: T J Carlson; Jeffrey P Jones; L Peterson; N Castagnoli; K R Iyer; William F Trager
Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(7):749-56.
1995: M He; Kent L Kunze; William F Trager
Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(6):659-63.
1995: R B Labroo; Kenneth E Thummel; Kent L Kunze; T Podoll; William F Trager; Evan D Kharasch
Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(4):490-6.
1994: J M Neal; William N Howald; Kent L Kunze; R F Lawrence; William F Trager
Application of negative-ion chemical ionization isotope dilution gas chromatography--mass spectrometry to single-dose bioavailability studies of mefloquine.
Journal of chromatography. B, Biomedical applications 1994;661(2):263-9.
1994: Stephen D Hall; Mitchell A Hamman; Allan E Rettie; L C Wienkers; William F Trager; Mark R VandenBranden; Steven A Wrighton
Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 1994;22(6):975-8.
1994: Kenneth E Thummel; Danny D Shen; T D Podoll; Kent L Kunze; William F Trager; C E Bacchi; Christopher L Marsh; John P McVicar; D M Barr; James D Perkins
Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.
The Journal of pharmacology and experimental therapeutics 1994;271(1):557-66.
1994: Kenneth E Thummel; Danny D Shen; T D Podoll; Kent L Kunze; William F Trager; P S Hartwell; V A Raisys; Christopher L Marsh; John P McVicar; D M Barr
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.
The Journal of pharmacology and experimental therapeutics 1994;271(1):549-56.
1994: J P Wang; Jashvant D Unadkat; S McNamara; T A O'Sullivan; Arnold L. Smith; William F Trager; Bonnie W Ramsey
Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis.
Clinical pharmacology and therapeutics 1994;55(5):528-34.
1994: Allan E Rettie; L C Wienkers; F J Gonzalez; William F Trager; Kenneth R Korzekwa
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.
Pharmacogenetics 1994;4(1):39-42.
1993: T A O'Sullivan; J P Wang; Jashvant D Unadkat; S M al-Habet; William F Trager; Arnold L. Smith; S McNamara; Moira L Aitken
Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis.
Clinical pharmacology and therapeutics 1993;54(3):323-8.
1993: Kent L Kunze; William F Trager
Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline.
Chemical research in toxicology 1993;6(5):649-56.
1992: R A O'Reilly; D A Goulart; Kent L Kunze; J Neal; M Gibaldi; A C Eddy; William F Trager
Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects.
Clinical pharmacology and therapeutics 1992;51(6):656-67.
1992: L D Heimark; L Wienkers; K Kunze; M Gibaldi; A C Eddy; William F Trager; R A O'Reilly; D A Goulart
The mechanism of the interaction between amiodarone and warfarin in humans.
Clinical pharmacology and therapeutics 1992;51(4):398-407.
1992: Allan E Rettie; Kenneth R Korzekwa; Kent L Kunze; R F Lawrence; A C Eddy; T Aoyama; H V Gelboin; F J Gonzalez; William F Trager
Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.
Chemical research in toxicology 1992;5(1):54-9.
1991: Kenneth R Korzekwa; William F Trager; S J Smith; Yoichi Osawa; J R Gillette
Theoretical studies on the mechanism of conversion of androgens to estrogens by aromatase.
Biochemistry 1991;30(25):6155-62.
1991: Kent L Kunze; A C Eddy; M Gibaldi; William F Trager
Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin.
Chirality 1991;3(1):24-9.
1990: Kenneth R Korzekwa; William F Trager; K Nagata; A Parkinson; J R Gillette
Isotope effect studies on the mechanism of the cytochrome P-450IIA1-catalyzed formation of delta 6-testosterone from testosterone.
Drug metabolism and disposition: the biological fate of chemicals 1990;18(6):974-9.
1990: S Ottoboni; T J Carlson; William F Trager; Kay Castagnoli; Neal Castagnoli
Studies on the cytochrome P-450 catalyzed ring alpha-carbon oxidation of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Chemical research in toxicology 1990;3(5):423-7.
1990: Kenneth R Korzekwa; William N Howald; William F Trager
The use of Brauman's least squares approach for the quantification of deuterated chlorophenols.
Biomedical & environmental mass spectrometry 1990;19(4):211-7.
1990: Jeffrey P Jones; Allan E Rettie; William F Trager
Intrinsic isotope effects suggest that the reaction coordinate symmetry for the cytochrome P-450 catalyzed hydroxylation of octane is isozyme independent.
Journal of medicinal chemistry 1990;33(4):1242-6.
1990: R F Lawrence; Allan E Rettie; A C Eddy; William F Trager
Chemical synthesis, absolute configuration, and stereochemistry of formation of 10-hydroxywarfarin: a major oxidative metabolite of (+)-(R)-warfarin from hepatic microsomal preparations.
Chirality 1990;2(2):96-105.
1989: Kenneth R Korzekwa; D C Swinney; William F Trager
Isotopically labeled chlorobenzenes as probes for the mechanism of cytochrome P-450 catalyzed aromatic hydroxylation.
Biochemistry 1989;28(23):9019-27.
1989: Kenneth R Korzekwa; William F Trager; J R Gillette
Theory for the observed isotope effects from enzymatic systems that form multiple products via branched reaction pathways: cytochrome P-450.
Biochemistry 1989;28(23):9012-8.
1989: Allan E Rettie; A C Eddy; L D Heimark; M Gibaldi; William F Trager
Characteristics of warfarin hydroxylation catalyzed by human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 1989;17(3):265-70.
1989: Kenneth R Korzekwa; K Nagata; William F Trager; J R Gillette
Metabolism of the B-ring of testosterone by the rat cytochrome P-450 system.
Drug metabolism reviews 1989;20(2-4):535-9.
1989: William F Trager
Stereochemistry of cytochrome P-450 reactions.
Drug metabolism reviews 1989;20(2-4):489-96.
1987: L D Heimark; M Gibaldi; William F Trager; R A O'Reilly; D A Goulart
The mechanism of the warfarin-rifampin drug interaction in humans.
Clinical pharmacology and therapeutics 1987;42(4):388-94.
1987: L D Heimark; S Toon; M Gibaldi; William F Trager; R A O'Reilly; D A Goulart
The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans.
Clinical pharmacology and therapeutics 1987;42(3):312-9.
1987: R A O'Reilly; William F Trager; A E Rettie; D A Goulart
Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans.
Clinical pharmacology and therapeutics 1987;42(3):290-4.
1986: S Toon; L K Low; M Gibaldi; William F Trager; R A O'Reilly; C H Motley; D A Goulart
The warfarin-sulfinpyrazone interaction: stereochemical considerations.
Clinical pharmacology and therapeutics 1986;39(1):15-24.
1985: S Toon; L D Heimark; William F Trager; R A O'Reilly
Metabolic fate of phenprocoumon in humans.
Journal of pharmaceutical sciences 1985;74(10):1037-40.
1985: E D Bush; William F Trager
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
Journal of medicinal chemistry 1985;28(8):992-6.
1985: L D Heimark; William F Trager
Stereoselective metabolism of conformational analogues of warfarin by beta-naphthoflavone-inducible cytochrome P-450.
Journal of medicinal chemistry 1985;28(4):503-6.
1985: L D Heimark; William F Trager
A stable isotope assay for phenprocoumon and its metabolites.
Biomedical mass spectrometry 1985;12(2):67-71.
1984: S Toon; William F Trager
Pharmacokinetic implications of stereoselective changes in plasma-protein binding: warfarin/sulfinpyrazone.
Journal of pharmaceutical sciences 1984;73(11):1671-3.
1984: L D Heimark; William F Trager
The preferred solution conformation of warfarin at the active site of cytochrome P-450 based on the CD spectra in octanol/water model system.
Journal of medicinal chemistry 1984;27(8):1092-5.
1984: D C Swinney; William N Howald; William F Trager
Intramolecular isotope effects associated with meta-hydroxylation of biphenyl catalyzed by cytochrome P-450.
Biochemical and biophysical research communications 1984;118(3):867-72.
1983: E D Bush; L K Low; William F Trager
A sensitive and specific stable isotope assay for warfarin and its metabolites.
Biomedical mass spectrometry 1983;10(7):395-8.
1982: E D Bush; William F Trager
Evidence against an abstraction or direct insertion mechanism for cytochrome P-450 catalysed meta hydroxylations.
Biochemical and biophysical research communications 1982;104(2):626-32.
1980: I H Patel; R H Levy; J M Neal; William F Trager
Simultaneous analysis of phenobarbital and p-hydroxyphenobarbital in biological fluids by GLC-chemical-ionization mass spectrometry.
Journal of pharmaceutical sciences 1980;69(10):1218-9.
1980: R A O'Reilly; William F Trager; C H Motley; William N Howald
Interaction of secobarbital with warfarin pseudoracemates.
Clinical pharmacology and therapeutics 1980;28(2):187-95.
1980: R A O'Reilly; William F Trager; C H Motley; William N Howald
Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man.
The Journal of clinical investigation 1980;65(3):746-53.
1980: William N Howald; E D Bush; William F Trager; R A O"Reilly; C H Motley
A stable isotope assay for pseudoracemic warfarin from human plasma samples.
Biomedical mass spectrometry 1980;7(1):35-40.